<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489853</url>
  </required_header>
  <id_info>
    <org_study_id>D5892C00014</org_study_id>
    <secondary_id>Eudract No: 2006-006519-60</secondary_id>
    <nct_id>NCT00489853</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD</brief_title>
  <acronym>CODEX</acronym>
  <official_title>A Multi-centre, Randomised, Double-blind, Cross-over Design Study to Evaluate Efficacy on Exercise Tolerance of Symbicort ®(Budesonide/Formoterol) 320/9μg One Inhalation Twice Daily Compared With Placebo and Oxis® 9μg One Inhalation Twice Daily in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect on exercise tolerance, lung function
      and symptoms after treatment with Symbicort, Oxis or placebo in patients with severe chronic
      obstructive pulmonary disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 1 Hour Post-dose</measure>
    <time_frame>Single measurement taken1 hour post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 6 Hour Post-dose</measure>
    <time_frame>Single measurement taken 6 hours post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Flow (FEV1) Pre-dose</measure>
    <time_frame>Pre-dose at the start of treatment and pre-dose after one week of treatment</time_frame>
    <description>The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Pre-dose</measure>
    <time_frame>Pre-dose at the start of treatment and pre-dose after one week of treatment</time_frame>
    <description>The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Capacity (VC) Pre-dose (Change From Pre-treatment to Treatment)</measure>
    <time_frame>Pre-dose at the start of treatment and pre-dose after one week of treatment</time_frame>
    <description>The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF) Before Morning Dose</measure>
    <time_frame>Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period</time_frame>
    <description>The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Score</measure>
    <time_frame>Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period</time_frame>
    <description>The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (symptoms did not cause a sleep problem) to 4 (did not sleep at all due to symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breathlessness Score</measure>
    <time_frame>Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period</time_frame>
    <description>The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any difficulty in breathing) to 4 (almost constant difficulties in breathing). All patients with data from both periods are included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest Tightness Score</measure>
    <time_frame>Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period</time_frame>
    <description>The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any discomfort) to 4 (almost constant discomfort).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough Score</measure>
    <time_frame>Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period</time_frame>
    <description>The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of coughing) to 4 (never free of need to cough).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Inhalations of Reliever Medication</measure>
    <time_frame>Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period</time_frame>
    <description>The change in average daily use for the run-in or wash-out period to the average daily use of the subsequent treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg CR10 Score Before Exercise Endurance Time (EET) Performed 1 Hour Post-dose</measure>
    <time_frame>Single measurement performed at rest prior to exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
    <description>The Borg CR10 Scale consists of 10-point score that the patients pointed to so as to indicate their level of dyspnea before and during exercise testing (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness. Patients are allowed to assign an even higher number depending on their perceived level of breathlessness).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg CR10 Score After Exercise Endurance Time (EET) Performed 1 Hour Post-dose</measure>
    <time_frame>Single measurement performed after exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
    <description>The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to &gt;10 (absolute maximum breathing discomfort).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg CR10 Score Before Exercise Endurance Time (EET) Performed 6 Hour Post-dose</measure>
    <time_frame>Single measurement performed at rest prior to exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
    <description>The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to &gt;10 (absolute maximum breathing discomfort).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg CR10 Score After Exercise Endurance Time (EET) Performed 6 Hours Post-dose</measure>
    <time_frame>Single measurement performed after exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
    <description>The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to &gt;10 (absolute maximum breathing discomfort). All patients with data are included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 1 Hour Postdose</measure>
    <time_frame>Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual participant data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 6 Hours Post-dose</measure>
    <time_frame>Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual participant data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Capacity (VC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)</measure>
    <time_frame>Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual participant data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)</measure>
    <time_frame>Single measurement obtained before exercise endurance test performed 1hour post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual participant data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)</measure>
    <time_frame>Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual participant data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Volume (RV) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)</measure>
    <time_frame>Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual participant data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)</measure>
    <time_frame>Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual participant data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)</measure>
    <time_frame>Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual participant data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Capacity (VC) (Body Plethysmography) Performed Before 6 Hour Exercise Endurance Time (EET)</measure>
    <time_frame>Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual participant data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)</measure>
    <time_frame>Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual participant data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)</measure>
    <time_frame>Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual participant data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Volume (RV) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)</measure>
    <time_frame>Single measurement obtained before exercise endurance test performed 6 hous post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual participant data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)</measure>
    <time_frame>Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual participant data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 6 Hours Post-dose EET</measure>
    <time_frame>Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
    <description>Treatment means from individual participant data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SGRQ-C (St. George's Respiratory Questionnaire for COPD Patients) Total Score</measure>
    <time_frame>Single measurement taken at the end of each 1-week treatment period</time_frame>
    <description>Score from a questionnaire, with scores ranging form 0 (perfect health) to 100 (worst possible state). Includes all patients with data.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Symbicort then Formoterol then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol then Symbicort then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Formoterol then Symbicort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide/formoterol Turbuhaler 320/9µg</intervention_name>
    <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms</description>
    <arm_group_label>Symbicort then Formoterol then Placebo</arm_group_label>
    <arm_group_label>Formoterol then Symbicort then Placebo</arm_group_label>
    <arm_group_label>Placebo then Formoterol then Symbicort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>formoterol Turbuhaler 9µg</intervention_name>
    <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
    <arm_group_label>Symbicort then Formoterol then Placebo</arm_group_label>
    <arm_group_label>Formoterol then Symbicort then Placebo</arm_group_label>
    <arm_group_label>Placebo then Formoterol then Symbicort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 1 inhalation twice daily</description>
    <arm_group_label>Symbicort then Formoterol then Placebo</arm_group_label>
    <arm_group_label>Formoterol then Symbicort then Placebo</arm_group_label>
    <arm_group_label>Placebo then Formoterol then Symbicort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;=40 years of age

          -  diagnosed COPD with symptoms &gt;= 2 years

          -  pre-bronchodilatory FEV1 &lt;=50% of PN

        Exclusion Criteria:

          -  Current respiratory tract disorder other than COPD

          -  history of asthma or rhinitis

          -  significant or unstable cardiovascular disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas Andersson, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heinrich Worth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akademisches Lehrkrankenhaus der Universität Erlangen-Nürnberg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Furth</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geesthacht</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grobhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Neuruppin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Basel</city>
        <state>Basel Stadt</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.astrazeneca.com/node/emailtriage.aspx</url>
    <description>AstraZeneca Clinical Trial Information - Outside US</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2007</study_first_submitted>
  <study_first_submitted_qc>June 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <results_first_submitted>August 6, 2009</results_first_submitted>
  <results_first_submitted_qc>July 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 30, 2012</results_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited in 12 centers in Germany and 12 centers in Switzerland.</recruitment_details>
      <pre_assignment_details>Among 137 enrolled patients, 26 patients were not randomised (14 due to violation of inclusion/exclusion criteria, 2 due to adverse events, 1 due to development of study-specific discontinuation criteria, 7 due to voluntary discontinuation, 1 due to lost to follow-up, and 1 due to other reason.)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Symbicort Then Formoterol Then Placebo</title>
          <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily</description>
        </group>
        <group group_id="P2">
          <title>Formoterol Then Symbicort Then Placebo</title>
          <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo Then Formoterol Then Symbicort</title>
          <description>Placebo, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash-out Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study-specific discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash-out Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study specific discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study specific discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Cross over study with 3 Arms. (1)Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily. (2)Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily. (3) Placebo, 1 inhalation twice daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" lower_limit="42" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 1 Hour Post-dose</title>
        <description>Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods.</description>
        <time_frame>Single measurement taken1 hour post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 1 Hour Post-dose</title>
          <description>Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods.</description>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="529" spread="377"/>
                    <measurement group_id="O2" value="441" spread="292"/>
                    <measurement group_id="O3" value="406" spread="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 6 Hour Post-dose</title>
        <description>Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods.</description>
        <time_frame>Single measurement taken 6 hours post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 6 Hour Post-dose</title>
          <description>Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods.</description>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463" spread="312"/>
                    <measurement group_id="O2" value="408" spread="283"/>
                    <measurement group_id="O3" value="388" spread="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Flow (FEV1) Pre-dose</title>
        <description>The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.</description>
        <time_frame>Pre-dose at the start of treatment and pre-dose after one week of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Flow (FEV1) Pre-dose</title>
          <description>The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0830" spread="0.2480"/>
                    <measurement group_id="O2" value="0.0630" spread="0.2500"/>
                    <measurement group_id="O3" value="-0.046" spread="0.1830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Pre-dose</title>
        <description>The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.</description>
        <time_frame>Pre-dose at the start of treatment and pre-dose after one week of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Pre-dose</title>
          <description>The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.060" spread="0.406"/>
                    <measurement group_id="O2" value="0.067" spread="0.407"/>
                    <measurement group_id="O3" value="-0.094" spread="0.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Capacity (VC) Pre-dose (Change From Pre-treatment to Treatment)</title>
        <description>The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.</description>
        <time_frame>Pre-dose at the start of treatment and pre-dose after one week of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Capacity (VC) Pre-dose (Change From Pre-treatment to Treatment)</title>
          <description>The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.105" spread="0.3600"/>
                    <measurement group_id="O2" value="0.089" spread="0.370"/>
                    <measurement group_id="O3" value="-0.083" spread="0.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow (PEF) Before Morning Dose</title>
        <description>The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period.</description>
        <time_frame>Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow (PEF) Before Morning Dose</title>
          <description>The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period.</description>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="32.70"/>
                    <measurement group_id="O2" value="5.60" spread="21.50"/>
                    <measurement group_id="O3" value="-10.00" spread="27.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Score</title>
        <description>The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (symptoms did not cause a sleep problem) to 4 (did not sleep at all due to symptoms).</description>
        <time_frame>Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Score</title>
          <description>The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (symptoms did not cause a sleep problem) to 4 (did not sleep at all due to symptoms).</description>
          <units>Score on Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.70" spread="0.47"/>
                    <measurement group_id="O2" value="-0.03" spread="0.47"/>
                    <measurement group_id="O3" value="0.11" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breathlessness Score</title>
        <description>The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any difficulty in breathing) to 4 (almost constant difficulties in breathing). All patients with data from both periods are included.</description>
        <time_frame>Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Breathlessness Score</title>
          <description>The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any difficulty in breathing) to 4 (almost constant difficulties in breathing). All patients with data from both periods are included.</description>
          <units>Score on Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.54"/>
                    <measurement group_id="O2" value="-0.40" spread="0.46"/>
                    <measurement group_id="O3" value="0.15" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chest Tightness Score</title>
        <description>The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any discomfort) to 4 (almost constant discomfort).</description>
        <time_frame>Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Chest Tightness Score</title>
          <description>The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any discomfort) to 4 (almost constant discomfort).</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.46"/>
                    <measurement group_id="O2" value="-0.02" spread="0.47"/>
                    <measurement group_id="O3" value="0.17" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cough Score</title>
        <description>The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of coughing) to 4 (never free of need to cough).</description>
        <time_frame>Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Cough Score</title>
          <description>The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of coughing) to 4 (never free of need to cough).</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.51"/>
                    <measurement group_id="O2" value="-0.05" spread="0.50"/>
                    <measurement group_id="O3" value="0.10" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Inhalations of Reliever Medication</title>
        <description>The change in average daily use for the run-in or wash-out period to the average daily use of the subsequent treatment period.</description>
        <time_frame>Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Inhalations of Reliever Medication</title>
          <description>The change in average daily use for the run-in or wash-out period to the average daily use of the subsequent treatment period.</description>
          <units>Number of inhalations during 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="1.51"/>
                    <measurement group_id="O2" value="-0.36" spread="1.26"/>
                    <measurement group_id="O3" value="0.51" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Borg CR10 Score Before Exercise Endurance Time (EET) Performed 1 Hour Post-dose</title>
        <description>The Borg CR10 Scale consists of 10-point score that the patients pointed to so as to indicate their level of dyspnea before and during exercise testing (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness. Patients are allowed to assign an even higher number depending on their perceived level of breathlessness).</description>
        <time_frame>Single measurement performed at rest prior to exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Borg CR10 Score Before Exercise Endurance Time (EET) Performed 1 Hour Post-dose</title>
          <description>The Borg CR10 Scale consists of 10-point score that the patients pointed to so as to indicate their level of dyspnea before and during exercise testing (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness. Patients are allowed to assign an even higher number depending on their perceived level of breathlessness).</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="3.2"/>
                    <measurement group_id="O2" value="3.4" spread="3.1"/>
                    <measurement group_id="O3" value="3.9" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Borg CR10 Score After Exercise Endurance Time (EET) Performed 1 Hour Post-dose</title>
        <description>The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to &gt;10 (absolute maximum breathing discomfort).</description>
        <time_frame>Single measurement performed after exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Borg CR10 Score After Exercise Endurance Time (EET) Performed 1 Hour Post-dose</title>
          <description>The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to &gt;10 (absolute maximum breathing discomfort).</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="2.7"/>
                    <measurement group_id="O2" value="11.6" spread="2.9"/>
                    <measurement group_id="O3" value="11.4" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Borg CR10 Score Before Exercise Endurance Time (EET) Performed 6 Hour Post-dose</title>
        <description>The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to &gt;10 (absolute maximum breathing discomfort).</description>
        <time_frame>Single measurement performed at rest prior to exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Borg CR10 Score Before Exercise Endurance Time (EET) Performed 6 Hour Post-dose</title>
          <description>The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to &gt;10 (absolute maximum breathing discomfort).</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="3.2"/>
                    <measurement group_id="O2" value="3.4" spread="3.1"/>
                    <measurement group_id="O3" value="3.9" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Borg CR10 Score After Exercise Endurance Time (EET) Performed 6 Hours Post-dose</title>
        <description>The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to &gt;10 (absolute maximum breathing discomfort). All patients with data are included.</description>
        <time_frame>Single measurement performed after exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Borg CR10 Score After Exercise Endurance Time (EET) Performed 6 Hours Post-dose</title>
          <description>The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to &gt;10 (absolute maximum breathing discomfort). All patients with data are included.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="2.9"/>
                    <measurement group_id="O2" value="11.5" spread="3.1"/>
                    <measurement group_id="O3" value="11.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 1 Hour Postdose</title>
        <description>Treatment means from individual participant data.</description>
        <time_frame>Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 1 Hour Postdose</title>
          <description>Treatment means from individual participant data.</description>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" spread="0.85"/>
                    <measurement group_id="O2" value="2.10" spread="0.82"/>
                    <measurement group_id="O3" value="1.97" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 6 Hours Post-dose</title>
        <description>Treatment means from individual participant data.</description>
        <time_frame>Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 6 Hours Post-dose</title>
          <description>Treatment means from individual participant data.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="0.79"/>
                    <measurement group_id="O2" value="2.12" spread="0.80"/>
                    <measurement group_id="O3" value="1.85" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Capacity (VC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)</title>
        <description>Treatment means from individual participant data.</description>
        <time_frame>Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Capacity (VC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)</title>
          <description>Treatment means from individual participant data.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" spread="0.72"/>
                    <measurement group_id="O2" value="2.73" spread="0.77"/>
                    <measurement group_id="O3" value="2.37" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)</title>
        <description>Treatment means from individual participant data.</description>
        <time_frame>Single measurement obtained before exercise endurance test performed 1hour post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)</title>
          <description>Treatment means from individual participant data.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" spread="0.61"/>
                    <measurement group_id="O2" value="2.18" spread="0.70"/>
                    <measurement group_id="O3" value="1.91" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)</title>
        <description>Treatment means from individual participant data.</description>
        <time_frame>Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)</title>
          <description>Treatment means from individual participant data.</description>
          <units>Liters</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.59" spread="1.69"/>
                    <measurement group_id="O2" value="5.66" spread="1.61"/>
                    <measurement group_id="O3" value="5.79" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Volume (RV) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)</title>
        <description>Treatment means from individual participant data.</description>
        <time_frame>Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Volume (RV) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)</title>
          <description>Treatment means from individual participant data.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="1.59"/>
                    <measurement group_id="O2" value="4.94" spread="1.62"/>
                    <measurement group_id="O3" value="5.13" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)</title>
        <description>Treatment means from individual participant data.</description>
        <time_frame>Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)</title>
          <description>Treatment means from individual participant data.</description>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.58" spread="1.71"/>
                    <measurement group_id="O2" value="7.62" spread="1.68"/>
                    <measurement group_id="O3" value="7.45" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)</title>
        <description>Treatment means from individual participant data.</description>
        <time_frame>Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)</title>
          <description>Treatment means from individual participant data.</description>
          <units>kilopascal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" spread="1.66"/>
                    <measurement group_id="O2" value="2.98" spread="1.81"/>
                    <measurement group_id="O3" value="4.22" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Capacity (VC) (Body Plethysmography) Performed Before 6 Hour Exercise Endurance Time (EET)</title>
        <description>Treatment means from individual participant data.</description>
        <time_frame>Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Capacity (VC) (Body Plethysmography) Performed Before 6 Hour Exercise Endurance Time (EET)</title>
          <description>Treatment means from individual participant data.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="0.730"/>
                    <measurement group_id="O2" value="2.64" spread="0.78"/>
                    <measurement group_id="O3" value="2.42" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)</title>
        <description>Treatment means from individual participant data.</description>
        <time_frame>Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)</title>
          <description>Treatment means from individual participant data.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" spread="0.60"/>
                    <measurement group_id="O2" value="2.08" spread="0.69"/>
                    <measurement group_id="O3" value="1.92" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)</title>
        <description>Treatment means from individual participant data.</description>
        <time_frame>Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)</title>
          <description>Treatment means from individual participant data.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.47" spread="1.65"/>
                    <measurement group_id="O2" value="5.49" spread="1.45"/>
                    <measurement group_id="O3" value="5.82" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Volume (RV) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)</title>
        <description>Treatment means from individual participant data.</description>
        <time_frame>Single measurement obtained before exercise endurance test performed 6 hous post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Volume (RV) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)</title>
          <description>Treatment means from individual participant data.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" spread="1.63"/>
                    <measurement group_id="O2" value="4.79" spread="1.52"/>
                    <measurement group_id="O3" value="5.19" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)</title>
        <description>Treatment means from individual participant data.</description>
        <time_frame>Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)</title>
          <description>Treatment means from individual participant data.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.41" spread="1.68"/>
                    <measurement group_id="O2" value="7.37" spread="1.55"/>
                    <measurement group_id="O3" value="7.63" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 6 Hours Post-dose EET</title>
        <description>Treatment means from individual participant data.</description>
        <time_frame>Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 6 Hours Post-dose EET</title>
          <description>Treatment means from individual participant data.</description>
          <units>Kilopascals</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="1.68"/>
                    <measurement group_id="O2" value="3.20" spread="2.02"/>
                    <measurement group_id="O3" value="4.12" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SGRQ-C (St. George's Respiratory Questionnaire for COPD Patients) Total Score</title>
        <description>Score from a questionnaire, with scores ranging form 0 (perfect health) to 100 (worst possible state). Includes all patients with data.</description>
        <time_frame>Single measurement taken at the end of each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, 1 inhalation twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>SGRQ-C (St. George's Respiratory Questionnaire for COPD Patients) Total Score</title>
          <description>Score from a questionnaire, with scores ranging form 0 (perfect health) to 100 (worst possible state). Includes all patients with data.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" spread="18"/>
                    <measurement group_id="O2" value="51.6" spread="19.2"/>
                    <measurement group_id="O3" value="54.5" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Symbicort</title>
          <description>Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily</description>
        </group>
        <group group_id="E2">
          <title>Formoterol</title>
          <description>Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo, 1 inhalation twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wrist Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chonic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to any publication or disclosure, the PI provides AstraZeneca with preliminary data and drafts and with the proposed final manuscript. AstraZeneca shall have a period of 30 days from receipt of the proposed final manuscript to review it and may within such time frame require that submission for publication or disclosure be delayed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

